Zobrazeno 21 - 30
of 2 157
pro vyhledávání: '"59"'
Autor:
Francesco Onida, Marie Robin, Xavier Poiré, Goda Choi, Christof Scheid, Ibrahim Yakoub-Agha, Linda Koster, Didier Blaise, Hendrik Veelken, Micha Srour, Yves Beguin, Nathalie Fegueux, Patrick Hayden, Francesca A M Kinsella, Thomas Schroeder, Jean-Henri Bourhis, Johan Maertens, Urpu Salmenniemi, Patrice Chevallier, Jan J. Cornelissen, Arancha Bermudez Rodriguez, Diderik-jan Eikeman, Jürgen Kuball, Jakob Passweg, Jennifer Byrne
Publikováno v:
Blood. 138:3953-3953
INTRODUCTION: Myelodysplastic Syndrome (MDS) is a heterogenous disease which is almost incurable without an allogeneic hematopoietic cell transplantation (allo-HCT). Within the revised international scoring system (R-IPSS), MDS with poor and very poo
Autor:
Kiran A Kumar, Praveen Ramakrishnan Geethakumari, Neil Desai, Syed Rizvi, Heather W. Goff, Akshat M Patel, J.L. Shah, Sofia F Yi
Publikováno v:
Blood. 138:1372-1372
Introduction Cutaneous T-cell lymphoma (CTCL) is a rare form of lymphoma that is characterized by the localization of malignant cells to the skin. While considerable advances have been made in both the diagnosis and treatment of this disease, managem
Autor:
Mark J. Levis, Vijayalakshmi Chandrasekaran, Divya Chakravarthy, Vinod Pullarkat, Gabriel N. Mannis, Harry P. Erba, Stefan Faderl, Tara L. Lin, Ronald S. Cheung, Stephen A. Strickland
Publikováno v:
Blood. 138:1268-1268
Introduction: CPX-351 (United States: Vyxeos ®; Europe: Vyxeos ® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved for the treatment of newly diagnosed therapy-related acute
Autor:
Guillermo Montalban Bravo, Naveen Pemmaraju, Gautam Borthakur, Elias Jabbour, Nicholas J. Short, Kelly S. Chien, Rashmi Kanagal-Shamanna, Yesid Alvarado, Hui Yang, Hagop M. Kantarjian, Jorge E. Cortes, Koji Sasaki, Tapan M. Kadia, Farhad Ravandi, Guillermo Garcia-Manero
Publikováno v:
Blood. 136:46-47
Background: Low-dose hypomethylating agents (HMAs) (azacitadine or decitabine) are safe and effective in patients with myelodysplastic syndromes (MDS). The aims of this study are to report the long-term follow-up of the phase 2 study of azacitidine o
Autor:
Elisabetta Todisco, Nicola Fracchiolla, Cristina Papayannidis, Maria Paola Martelli, Giuliana Rizzuto, Alessandro Cignetti, Nicola Di Renzo, Patrizia Zappasodi, Michele Gottardi, Ernesta Audisio, Monia Lunghi, Federica Gigli, Corrado Tarella, Chiara Zingaretti, Elisabetta Petracci, Roberta Volpi, Delia Cangini, Maria Benedetta Giannini, Mariarita Sciumè, Giuseppe Rossi, Avalon Group, Giovanni Martinelli, Claudio Cerchione
Publikováno v:
Blood. 136:37-38
Background This non-interventional retrospective study, is intended to analyze toxicity and effectiveness of venetoclax of a large cohort of R/R and de novo AML patients treated in Italy since 2015 outside clinical trials with the ultimate goal of im
Autor:
Douglas A. Stewart, Farheen Manji
Publikováno v:
Blood. 136:17-18
Introduction: Relapsed/refractory diffuse large B cell lymphoma (DLBCL) is an aggressive disease associated with a poor prognosis. Chimeric antigen receptor T cell (CAR-T) therapy is now approved for patients with relapsed/refractory DLBCL who have r
Autor:
Amine Belhabri, Mauricette Michallet, Emmanuelle Nicolas-Virelizier, Stephane Morisset, Souad Assad, Philippe Rey, Anne-Sophie Michallet, Sandrine Hayette, Laure Lebras, Yann Guillermin, Maël Heiblig, Isabelle Tigaud, Liliana Vila, Clémence Santana
Publikováno v:
Blood. 136:27-28
Background:Therapy related acute myeloid leukemia (t-AML) is a late complication following cytotoxic therapy for a primary neoplasm or a non-neoplastic disorder as autoimmune diseases and a highly fatal complication in patients treated for first prim
Autor:
Zhao Wang, Yuqin Song, Pian Zhang, Jun Zhu, Hongxia Zheng, Su Yang, Mingzhi Zhang, Wenyu Li, Zhitao Ying, Hui Liu, Zisong Zhou, Haiyan Yang, Ye Guo, Daobin Zhou, Jianqiu Wu, Dehui Zou
Publikováno v:
Blood. 136:39-40
Currently, no CAR-T product has been approved for use in China despite having hundreds of active CAR-T trials. Relma-cel (JWCAR029) is a CAR-T product with a CAR construct comprised of a binding domain, derived from a murine CD19-specific mAb (FMC63)
Autor:
Ian Chau, Kabir Mohammed, Bhupinder Sharma, Alinane Munyenyembe, Tasneem Elnafie, Tatiana Elwes, Dima El-Sharkawi, David Cunningham, Sunil Iyengar, Sarah Thompson, Wilam Alfred
Publikováno v:
Blood. 136:31-32
Introduction Following completion of chemotherapy with curative intent for DLBCL, for those in remission (CR), numerous national and international guidelines suggest on-going follow-up primarily to detect relapse of disease. For example, the NCCN gui
Autor:
Sikander Abdullah, Muhammad Jahanzeb Khalil, Hamid Ehsan, Faiz Anwer, Muhammad Khawar Sana, Mohammad Ammad Ud Din, Karun Neupane, Amrat Ehsan, Syed Ziauddin A. Zaidi, Qasim Khurshid, Mobeen Zaka Haider, Syed Maaz Abdullah, Muhammad Tayyeb, Abdul Jabbar Dar
Publikováno v:
Blood. 136:3-4
Introduction: Primary CNS lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma (NHL) variant limited to the CNS with rare evidence of systemic spread. It constitutes 4% of all CNS malignancies. Owing to the impenetrable blood-brain barrier to